Providing a More Competitive Environment

According to market analysis firm Evaluate Pharma, the global biopharmaceutical market is expected to grow continuously, reaching $505 billion by 2026. Incheon International Airport is positioning itself to dominate the high-value-added pharmaceutical air transport market—which is recognized as a new growth cargo sector—and is building an industrial ecosystem where air transport stakeholders can prosper together. As part of its airport community, Incheon International Airport obtained the CEIV Pharma certification in 2019 from the International Air Transport Association (IATA), which acknowledges its capability in handling pharmaceutical transportation. Recognized for its ability to handle temperature-controlled, time-sensitive pharmaceutical products such as vaccines, Incheon International Airport has demonstrated its top-level expertise in transporting COVID-19 diagnostic kits and vaccines worldwide since the onset of the pandemic. Furthermore, the airport renewed its certification in September 2022, ensuring the ability to maintain sustainable air transport quality (re-certification is conducted every three years based on rigorous on-site audits and evaluations).